| Patient | David Hume |
|---|---|
| Date of birth | 1711-05-07 |
| Identifiers | MRN HR-EN012-SYN-TD; SSN (made up) 000-12-3049 |
| Document date | 1775-10-28 |
| Author | Fiona Gallacher, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Adult preventive visit; no new complaints. [S]
Mr. Hume returns for the preventive visit that was postponed during chemotherapy. He finished his fourth and last cycle of adjuvant CAPOX three and a half weeks ago and was seen nine days ago to begin survivorship surveillance. His September cold cleared within ten days. The fingertip numbness from oxaliplatin is unchanged and does not affect buttoning or writing. His energy is returning; he walks 30 minutes most days and writes every morning. He has regained a little weight. He completed the health risk assessment before the visit. [S]
| Element | Detail |
|---|---|
| Visit | Adult preventive visit, age 64 |
| Recent treatment | Adjuvant CAPOX completed three and a half weeks ago |
| Active conditions | Resected stage IIIB colon cancer under surveillance; grade 1 oxaliplatin neuropathy; liver hemangioma |
| Medicines | None regularly since chemotherapy ended |
| Functional status | Independent; walking 30 minutes most days |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, and improving since chemotherapy ended |
| Psychosocial | Large circle of friends; weekly suppers have resumed; no loneliness; no financial strain |
| Behavioral | Never smoker; red wine four or more evenings a week, one to two glasses, never six or more; diet rich in red meat and pastry; walks 30 minutes most days |
| Activities of daily living | Independent in all |
| Instrumental activities of daily living | Manages his own medicines, money, correspondence, and travel |
| Home safety | Smoke detectors working; uses a seat belt |
| Hearing and vision | Reading glasses; last eye examination more than two years ago; no hearing concern |
| Sleep | About seven hours a night |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; weight up 0.4 kg in nine days; no fever or night sweats |
| Eyes | Negative | No change in vision with reading glasses |
| Ears, nose, mouth, and throat | Negative | Cold resolved; no mouth sores |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | One or two formed stools a day; no blood, pain, or urgency |
| Genitourinary | Negative | No urinary symptoms; mild nocturia once a night |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | Palms and soles normal; no new skin lesions |
| Neurological | Positive | Stable fingertip and toe-tip numbness; no weakness, imbalance, or falls |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
| Hematologic | Negative | No easy bruising or bleeding |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferric carboxymaltose 750 mg intravenous infusion, two doses one week apart | 750 mg IV once a week for two doses | Intravenous route | 1775-06-01 to 1775-06-08 | completed | S |
| Capecitabine 500 mg oral tablet, four tablets (1749 mg, 1000 mg/m²) by mouth twice daily on days 1 to 14 of each 21-day cycle, four cycles | Four tablets twice daily on days 1 to 14 of each 21-day cycle | Oral route | 1775-07-20 to 1775-10-04 | completed | S |
| Oxaliplatin 130 mg/m² (260 mg) intravenous infusion on day 1 of each 21-day cycle, four cycles | 260 mg IV on day 1 every 21 days | Intravenous route | 1775-07-20 to 1775-09-21 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea during chemotherapy | One tablet every 8 hours as needed for nausea | Oral route | 1775-07-20 to 1775-10-04 | completed | S |
| Loperamide 2 mg oral capsule, two capsules after the first loose stool, then one after each loose stool, no more than eight a day | As needed for diarrhea on capecitabine | Oral route | 1775-07-20 to 1775-10-04 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1775-10-28 | Body height | 178 | cm | S |
| 1775-10-28 | Body weight | 81.4 | kg | S |
| 1775-10-28 | Body mass index (BMI) [Ratio] | 25.7 | kg/m2 | S |
| 1775-10-28 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1775-10-28 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1775-10-28 | Heart rate | 72 | /min | S |
| 1775-10-28 | Respiratory rate | 14 | /min | S |
| 1775-10-28 | Body temperature | 36.6 | Cel | S |
| 1775-10-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1775-10-28 | Cholesterol [Mass/volume] in Serum or Plasma | 196 | mg/dL | <=199 mg/dL | Normal | S |
| 1775-10-28 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 | mg/dL | >=40 mg/dL | Normal | S |
| 1775-10-28 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 118 | mg/dL | <=99 mg/dL | High | S |
| 1775-10-28 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 1775-10-28 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1775-10-28 | Total score [AUDIT-C] | 4 | {score} | S |
Vital signs recorded on 1775-10-28; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well-appearing; BMI 25.7 |
| Eyes | Pupils equal and reactive; conjunctivae pink |
| Ears, nose, and throat | Normal; no oral lesions |
| Neck | No thyroid enlargement or nodes; no carotid bruits |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Respiratory | Clear |
| Abdomen | Healed laparoscopic scars; soft, no masses, no liver enlargement |
| Lymph nodes | No cervical, axillary, or inguinal nodes |
| Neurological | Reduced light touch at the fingertips and toe tips; vibration slightly reduced at the toes; strength, reflexes, and gait normal |
| Skin | A few seborrheic keratoses; no suspicious lesions |
| Psychiatric | Cheerful, engaged, and good-humoured |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the sigmoid colon, suspected at presentation and confirmed by colonoscopic biopsy; synthetic modern diagnosis linked to the documented 1775 bowel disorder and its retrospective interpretation as colon cancer | active | confirmed | C18.7 | S — Synthetic diagnosis confirmed by biopsy and resection in the modern episode; the historical diagnosis remains a retrospective interpretation (R). |
| Iron deficiency anemia from chronic blood loss from the colon tumor | active | confirmed | D50.0 | S — Synthetic finding echoing the documented 'hemorrhage in the upper part of the intestines'; no blood count from his lifetime exists. |
| Hemangioma of the liver, 9 mm, segment VI; incidental finding characterized by MRI, not a metastasis | active | confirmed | D18.03 | S — Synthetic incidental finding; it addresses, and does not confirm, the unverified suggestion of liver spread. |
| Acute viral upper respiratory infection during adjuvant chemotherapy, without fever or neutropenia; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
| Oxaliplatin-induced sensory peripheral neuropathy, grade 1, fingertips and toe tips, without functional impairment | active | confirmed | G62.0 | S — Synthetic expected toxicity of adjuvant oxaliplatin. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, 1775-1776 | Completed today | Inactivated vaccine given today, three weeks after chemotherapy ended |
| Pneumococcal vaccine | Completed today | PCV20 given today; recommended for adults 50 and older; no further doses needed |
| COVID-19 vaccine, 1775-1776 | Due | Recommended; he will get it at his pharmacy |
| Recombinant zoster vaccine | Due | Two-dose series recommended at 50 and older; he chose to start it at his January visit |
| RSV vaccine | Due | Discussed because of his recent chemotherapy; he will decide at the pharmacy visit |
| Tetanus booster | Up to date | Tdap seven and a half years ago; next due in about two and a half years |
| Hepatitis B vaccine | Not indicated | Aged 60 or older without risk factors; offered and not wanted |
| Colorectal cancer screening | Not indicated | Replaced by cancer surveillance: colonoscopy one year after resection, in June |
| Prostate cancer screening | Declined | Shared decision-making about the small benefit and the risks of overdiagnosis; he chose not to have PSA testing |
| Hepatitis C and HIV screening | Ordered | One-time screening; no prior result on record; added to the next blood draw |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | Never smoker |
| Cholesterol screening and statin decision | Completed today | LDL 118 mg/dL; 10-year risk about 10 percent; diet and activity first by shared decision |
| Diabetes screening | Completed today | HbA1c 5.5% (BMI 25.7) |
| Blood pressure screening | Completed today | 122/74 mmHg |
| Depression screening | Completed today | PHQ-2 score 0 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C 4, positive; brief counseling given |
| Physical activity and diet counseling | Completed today | Goal of 150 minutes of walking a week and less red and processed meat |
| Eye examination | Due | More than two years since his last examination; he will book with his optometrist |
Immunizations given today: Influenza vaccine, 1775-1776 season; Pneumococcal conjugate vaccine PCV20 [S]
Guideline basis: Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age, United States, 2025 (2025)
Follow-up: Hepatitis C and HIV tests with the next blood draw. CT in December. Surveillance visit with CEA and the first zoster vaccine dose in January. Next preventive visit in one year. [S]
Voluntary advance care planning discussion of about 20 minutes, with his consent, prompted by his cancer diagnosis. He has named a health care agent and completed a written health care directive, now scanned into the chart. If the cancer recurs, he wants a frank account of the options and their expected benefit, and he would accept surgery or chemotherapy that offered a real chance of cure or of more good time. He would not want resuscitation or prolonged life support if recovery to independent life and work were not expected, and he would want comfort-focused care at home at the end of life. [S]